Comparative Pharmacology
Head-to-head clinical analysis: AEMCOLO versus TICAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEMCOLO versus TICAR.
AEMCOLO vs TICAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEMCOLO (crizotinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and mesenchymal-epithelial transition factor (MET). It inhibits ALK and ROS1 phosphorylation, blocking downstream signaling pathways involved in cell proliferation and survival.
Ticarcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is a time-dependent bactericidal agent.
AEMCOLO (rifamycin) delayed-release tablets: 600 mg orally twice daily for 3 days. Take with or without food.
3 g IV every 4 hours for pseudomonal infections; 3 g IV every 6 hours for less severe infections.
None Documented
None Documented
Clinical Note
moderateTicarcillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ticarcillin."
Clinical Note
moderateTicarcillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy."
Clinical Note
moderateTicarcillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Ticarcillin."
Clinical Note
moderateTerminal elimination half-life is approximately 18-22 hours, supporting once-daily dosing for maintained intraluminal concentrations.
Terminal elimination half-life is approximately 1.2 hours in adults with normal renal function. In renal impairment, half-life may extend to 15-20 hours; dose adjustment required for CrCl <60 mL/min.
Primarily fecal elimination as unchanged drug; approximately 90% of a dose is recovered in feces, with less than 1% excreted unchanged in urine. Biliary excretion accounts for the remainder.
Ticarcillin is primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for 90-95% of the dose. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antibiotic
Antibiotic
Ticarcillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Ticarcillin."